Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP): EFNS/PNS 2021 Criteria, Subtypes, and Autoimmune Nodopathies

Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP): EFNS/PNS 2021 Criteria, Subtypes, and Autoimmune Nodopathies

A comprehensive guideline to applying the EFNS/PNS 2021 diagnostic criteria, recognizing the five clinical subtypes, identifying the autoimmune nodopathies as a distinct entity, and navigating IVIG, SCIG, and rituximab treatment selection.

By gomdori · Neurology · 13 minute read

Executive Summary

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is the most common chronic immune-mediated neuropathy, characterized by symmetric proximal and distal weakness with sensory loss progressing or relapsing over at least 8 weeks — the temporal criterion that distinguishes it from acute Guillain-Barre syndrome. The EFNS/PNS 2021 diagnostic criteria combine clinical phenotype with electrodiagnostic demyelination thresholds and recognize five clinical subtypes (typical, distal acquired demyelinating symmetric / DADS, multifocal / MADSAM, pure motor, pure sensory). The 2021 criteria formally separated autoimmune nodopathies (anti-NF155, anti-CNTN1, anti-Caspr1, anti-NF186) as a distinct disease entity with distinctive features (rapid severe onset, sensory ataxia, tremor, IgG4 antibodies, IVIG refractoriness, dramatic rituximab response). Treatment of classical CIDP combines IVIG (2 g/kg over 2-5 days induction, then 1 g/kg every 3 weeks maintenance), subcutaneous immunoglobulin (SCIG, Hizentra 0.2-0.4 g/kg weekly), plasma exchange, or corticosteroids as first-line with equivalent efficacy; rituximab is first-line for nodopathies and second-line for refractory typical CIDP.

≥8wk
Progression / relapse for CIDP (vs <4wk GBS)
5
Clinical subtypes per EFNS/PNS 2021
~10%
Nodopathies (separate entity)
70-80%
Respond to first-line IVIG/PLEX/steroid

S1. Pathophysiology and Clinical Subtypes

CIDP is an acquired immune-mediated demyelinating polyradiculoneuropathy of the peripheral nervous system. The pathophysiology involves T-cell and B-cell-mediated attack against myelin and Schwann cells, with macrophage-mediated demyelination, complement activation, and antibody-mediated injury at multiple sites along peripheral nerves and roots. The result is segmental demyelination producing conduction block, conduction slowing, and prolonged latencies on nerve conduction studies, with secondary axonal loss in chronic disease. Node of Ranvier antibody targets and segmental demyelination in CIDPCross-section of a myelinated peripheral axon: two Schwann-cell myelin internodes flank a node of Ranvier with paranodal loops. Antibody targets are mapped to their structures — anti-NF186 at the node, anti-NF155 at the glial paranodal loop, anti-contactin-1 and anti-Caspr1 at the axonal paranode. A demyelinated segment shows immune attack producing conduction block and slowing.Node of Ranvier: Antibody Targets & Segmental DemyelinationMyelin internode (Schwann cell)Myelin internode (Schwann cell)Node of RanvierparanodeparanodeAnti-NF186 (nodal)Anti-NF155glial paranodal loop; tremor, ataxiaAnti-CNTN1 / Anti-Caspr1axonal paranode; severe / sensory-painImmune attack → segmental demyelination → conduction failureNormal saltatory impulseSlowing / temporal dispersionConduction block

Five Clinical Subtypes (EFNS/PNS 2021)

SubtypeFrequencyDistinctive Features
Typical CIDP~50%Symmetric proximal AND distal weakness; sensory involvement; areflexia or hyporeflexia; progression/relapse ≥8 weeks
Distal CIDP (DADS — Distal Acquired Demyelinating Symmetric)~10%Distal-predominant symmetric weakness and sensory loss; often associated with anti-MAG IgM monoclonal gammopathy (more accurately paraproteinemic neuropathy); slower response to IVIG
MADSAM (Multifocal Acquired Demyelinating Sensory and Motor) / Lewis-Sumner~15%Asymmetric, multifocal sensorimotor deficits resembling mononeuritis multiplex but with demyelinating physiology; upper extremity predominance common
Pure motor CIDP~10%Symmetric weakness without sensory involvement; must distinguish from multifocal motor neuropathy (MMN, which is asymmetric and anti-GM1 positive)
Pure sensory CIDP (including CISP — chronic immune sensory polyradiculopathy)~10%Sensory ataxia and sensory loss without weakness; CISP variant has prominent ataxia from large fiber sensory loss

Demographics

  • Age: peak 50-70 years; can occur at any age including childhood
  • Sex: male predominance approximately 1.5-2:1
  • Annual incidence: approximately 1-2 per 100,000
  • Prevalence: approximately 5-10 per 100,000 (more common than ALS)
  • Family history: rare familial cases; mostly sporadic

Time Course

CIDP differs from acute Guillain-Barre syndrome (GBS) primarily by time course:

  • GBS: reaches nadir within 4 weeks of onset (typically 2-4 weeks)
  • CIDP: progresses or relapses for at least 8 weeks (often months to years)
  • Acute-onset CIDP (A-CIDP): 5-10% of CIDP cases present like GBS initially but continue progressing past 8 weeks, requiring reclassification
  • Subacute CIDP: progression between 4-8 weeks may be reclassified depending on continued progression
Pitfall — Acute-onset CIDP initially misdiagnosed as GBS. Approximately 5-10 percent of CIDP cases present with acute onset resembling GBS but continue to progress or relapse beyond 8 weeks. Initial IVIG or PLEX treatment for presumed GBS produces transient improvement followed by recurrent deterioration, which is the clue that CIDP is the actual diagnosis. Continued maintenance immunotherapy is then required. The diagnostic shift from GBS to CIDP fundamentally changes management from acute one-time treatment to chronic maintenance, with implications for prognosis counseling and long-term planning.

S2. EFNS/PNS 2021 Diagnostic Criteria

Diagnostic Framework

The EFNS/PNS 2021 criteria operate at three levels: CIDP, possible CIDP, and CIDP not confirmed. Each level requires specific combinations of clinical and electrodiagnostic features.

Clinical Criteria for Typical CIDP

Clinical CriterionRequirement
Weakness distributionSymmetric weakness of proximal AND distal muscles in upper and lower extremities
Sensory involvementSensory loss in distribution consistent with neuropathy
ReflexesAbsent or diminished tendon reflexes
Time courseProgression or relapsing course over at least 8 weeks
Absence of cranial nerve weaknessCranial nerve involvement supports nodopathy alternative

Electrodiagnostic Criteria for Demyelination

Demyelinating motor nerve conduction features must be present in at least 2 nerves per specified thresholds:

Electrodiagnostic FeatureThreshold for Demyelination
Prolonged distal motor latency (DML)>50% of upper limit of normal (ULN)
Reduced motor conduction velocity (MCV)<70% of lower limit of normal (LLN)
Prolonged F-wave latency>20% above ULN (>50% if amplitude greatly reduced)
Absent F-wavesIn 2 nerves with normal distal amplitude
Conduction block (motor)>50% reduction in CMAP amplitude between proximal and distal stimulation
Temporal dispersion>30% increase in CMAP duration between proximal and distal stimulation

Levels of Diagnostic Confidence

LevelRequirements
CIDP (definite)Clinical criteria + electrodiagnostic demyelinating criteria in 2 nerves
Possible CIDPClinical criteria + demyelinating features in 1 nerve OR clinical criteria + supportive features (CSF, MRI, US, biopsy, treatment response) without 2-nerve electrodiagnostic confirmation
CIDP not confirmedInadequate clinical or electrodiagnostic features; alternative diagnosis suggested

Supportive Criteria

  • CSF protein elevation (typically >45 mg/dL) with normal cell count (<10 cells/mm3) — albuminocytologic dissociation
  • MRI of brachial or lumbosacral plexus showing enlargement and/or gadolinium enhancement of nerve roots or plexus
  • Nerve ultrasound showing enlargement of nerves at proximal locations
  • Sural nerve biopsy showing onion-bulb formations and demyelination with mononuclear inflammatory infiltrate (rarely required in modern practice)
  • Objective response to immunotherapy (IVIG, steroids, or PLEX) within 4-12 weeks
Practice point — CSF and MRI are supportive, not required. The EFNS/PNS 2021 criteria position CSF (albuminocytologic dissociation) and MRI (nerve root enlargement and enhancement) as supportive features but not required for diagnosis. Their absence does not rule out CIDP if clinical and electrodiagnostic criteria are met. These tests are most useful in possible CIDP where electrodiagnostic criteria are not fully met or when alternative diagnoses are being actively considered.

S3. Nerve Conduction Studies, CSF, and Imaging

Optimal NCS Protocol for CIDP Diagnosis

Skilled and comprehensive nerve conduction studies are essential. Standard protocol: NCS motor CMAP waveforms: normal vs CIDP demyelinationMotor nerve conduction tracings. Top: normal nerve with brief distal latency, tall matched distal and proximal CMAPs, and preserved conduction velocity. Bottom: CIDP demyelinating nerve with prolonged distal motor latency, conduction block and temporal dispersion between distal and proximal stimulation, and slowed velocity. A panel lists the EFNS/PNS 2021 demyelination thresholds requiring at least two nerves.Motor NCS: Normal vs CIDP DemyelinationNormal nervestimulusdistal (wrist)proximal (elbow)short DMLmatched amplitudeCIDP demyelinating nerve↑ DML >150% ULNdistalproximaltemporal dispersionConduction block: >50% CMAP amplitude drop distal → proximalEFNS/PNS 2021 thresholdsDistal motor latency> 150% ULNMotor conduction velocity< 70% LLNF-wave latency> 120% ULNConduction block> 50% amplitude dropTemporal dispersion> 30% duration increaseAbsent F-wavesin 2 nervesDefinite CIDPcriteria met in≥ 2 motor nerves

  • Motor nerve studies: bilateral median, ulnar, peroneal, and tibial nerves at minimum; use proximal stimulation sites (axillary, supraclavicular, popliteal fossa) to detect conduction block and temporal dispersion
  • Sensory nerve studies: bilateral median, ulnar, sural nerves; SNAP amplitudes often reduced or absent in CIDP
  • F-wave studies: at least 10 F-waves per nerve; minimum F-wave latency assessment
  • Needle EMG: to assess for axonal loss (fibrillations, positive sharp waves) and chronicity (large polyphasic motor units)
  • Concentric needle electrodes preferred over monopolar for consistent amplitude measurements

CSF Analysis

CSF examination in CIDP characteristically shows:

  • Albuminocytologic dissociation: elevated protein (typically 45-200 mg/dL, sometimes higher) with normal cell count (<10 cells/mm3)
  • Cell count >10/mm3 should prompt consideration of alternative diagnoses (HIV, Lyme, sarcoidosis, lymphomatous neuropathy)
  • CSF oligoclonal bands typically negative; positive bands suggest alternative diagnosis
  • Very high CSF protein (>200 mg/dL) particularly characteristic of nodopathies (especially anti-NF155)
  • HIV antibody, Lyme serology, syphilis screen should accompany CSF in atypical cases

MRI of Plexus and Nerve Roots

MRI of the brachial plexus, lumbosacral plexus, and nerve roots with gadolinium contrast is highly supportive when positive:

  • Nerve root enlargement at exit foramina
  • Brachial or lumbosacral plexus enlargement
  • Gadolinium enhancement of nerve roots and plexus
  • Hypertrophy of cauda equina in advanced or longstanding disease
  • MRI is particularly useful when electrodiagnostic findings are inconclusive (possible CIDP) or when nodopathy with prominent nerve hypertrophy is suspected

Nerve Ultrasound

High-resolution nerve ultrasound (15-22 MHz transducers) is increasingly used as a non-invasive alternative to MRI:

  • Cross-sectional area enlargement at characteristic sites (median nerve at forearm, brachial plexus at supraclavicular region)
  • Pattern-based scoring systems (Bochum ultrasound score, Padua ultrasound score) help quantify findings
  • Useful for follow-up monitoring without contrast or radiation

Nerve Biopsy

Sural nerve biopsy is rarely required in modern practice given the strength of NCS, CSF, MRI, and antibody testing. Indications include:

  • Atypical features suggesting alternative diagnosis (vasculitis, amyloidosis, lymphomatous neuropathy)
  • Persistent diagnostic uncertainty after comprehensive workup
  • Suspected CISP (chronic immune sensory polyradiculopathy) where NCS may be normal

Findings include onion-bulb formations (recurrent demyelination-remyelination), demyelinated fibers with macrophage infiltration, perivascular mononuclear infiltrate, and endoneurial edema. Findings of axonal loss are common in chronic disease.

Required Antibody Panel

Modern CIDP workup requires antibody testing to identify the nodopathy subset that requires different treatment:

AntibodyAssociated PhenotypeTreatment Implication
Anti-NF155 (neurofascin 155)Subacute onset, severe weakness, tremor, sensory ataxia, very high CSF protein, IVIG-refractoryRituximab first-line; dramatic response
Anti-CNTN1 (contactin-1)Rapid onset, severe motor predominant, nephrotic syndrome rarelyRituximab first-line
Anti-Caspr1 (contactin-associated protein 1)Sensory predominant, neuropathic pain, sometimes cranial nerveRituximab first-line
Anti-NF186 (neurofascin 186)Less common; clinical features variableRituximab first-line
Anti-MAG IgM (paraproteinemic)DADS phenotype; IgM monoclonal gammopathyRituximab; sometimes IVIG; treat underlying paraprotein
Anti-GM1 IgMMultifocal motor neuropathy (MMN), not CIDPIVIG (steroids worsen MMN); not CIDP treatment
Practice point — Send nodal/paranodal antibody panel in any IVIG-refractory CIDP. The standard CIDP antibody panel includes anti-NF155, anti-CNTN1, anti-Caspr1, anti-NF186, and ideally anti-MAG IgM. When the patient fails to respond to first-line IVIG within 12 weeks, the panel must be sent before declaring treatment failure because the autoimmune nodopathies require rituximab rather than continued IVIG escalation. Sending this panel at initial diagnosis (before any treatment) is a reasonable approach in modern practice given the management implications.

S4. Autoimmune Nodopathies and Differential Diagnosis

The Autoimmune Nodopathies — A Distinct Entity

The EFNS/PNS 2021 criteria formally separated autoimmune nodopathies from CIDP as a distinct disease entity. This reclassification recognizes that these antibody-defined conditions have fundamentally different pathophysiology, clinical features, and treatment response than classical CIDP.

FeatureClassical CIDPAutoimmune Nodopathies
AntibodyNone identifiedAnti-NF155, anti-CNTN1, anti-Caspr1, anti-NF186 (IgG4 predominant)
OnsetInsidious over weeks-monthsRapid (weeks); severe
Weakness patternSymmetric proximal+distalOften severe; sometimes distal predominant
Sensory ataxiaVariableFrequent and severe
TremorUncommonCommon (especially anti-NF155)
Cranial nervesUncommonOccasional
CSF proteinMildly elevatedVery high (often >200 mg/dL)
Nerve hypertrophy on US/MRIMildPronounced
IVIG response70-80% respondPoor or absent response
Rituximab response40-50% (refractory cases)70-80% dramatic response

Differential Diagnosis

DifferentialDistinguishing FeaturesDecisive Test
Guillain-Barre syndrome (GBS)Acute onset (<4 weeks), monophasic; often post-infectiousTime course; serial assessment
POEMS syndromeOrganomegaly, endocrinopathy, lambda M-protein, elevated VEGF, sclerotic bone lesionsSerum VEGF + immunofixation + skeletal survey/PET
Multifocal motor neuropathy (MMN)Asymmetric pure motor, conduction block, anti-GM1 IgM; steroids WORSEN MMNAnti-GM1 IgM + asymmetric pure motor pattern
Anti-MAG paraproteinemic neuropathyDADS phenotype, IgM monoclonal gammopathy, slow onsetSPEP/immunofixation + anti-MAG IgM
Hereditary CMT (especially CMT1)Family history, foot deformity, slowly progressive over years/decades, no relapsesGenetic testing (PMP22, MPZ, GJB1)
Vasculitic neuropathyMononeuritis multiplex pattern, axonal physiology, systemic vasculitis featuresSural nerve biopsy + ANCA + systemic workup
Lymphomatous neuroinfiltrationPain, asymmetric, B symptoms, MRI/PET nerve uptakeMRI + nerve biopsy + lymphoma workup
Diabetic radiculoplexopathy / amyotrophyAsymmetric, painful, predominantly proximal lower extremity, diabeticClinical pattern + diabetes
HIV-associated CIDPHIV infection, CSF pleocytosis (>10 cells/mm3 typical)HIV testing
Lyme polyradiculitisEndemic exposure, painful, often facial nerve, CSF pleocytosisLyme serology + CSF
Sarcoid neuropathyOther sarcoidosis features, ACE, lymphadenopathyChest imaging + biopsy
Pearl — IVIG-refractory CIDP = check for nodopathy AND POEMS. The two conditions most often masquerading as IVIG-refractory CIDP are autoimmune nodopathies (anti-NF155 most common) and POEMS syndrome. Both require fundamentally different treatment than continued IVIG escalation. The standard for any patient who fails 12 weeks of IVIG is to send the complete panel: nodal/paranodal antibodies, serum and urine immunofixation, free light chains, serum VEGF, and FDG-PET or skeletal survey. Identifying either entity transforms management.
Pitfall — Treating MMN as CIDP with steroids. Multifocal motor neuropathy is asymmetric, pure motor, and anti-GM1 IgM positive. Critically, steroids WORSEN MMN (unlike CIDP where steroids are first-line). Misdiagnosing MMN as CIDP and treating with prednisone leads to progressive weakness and disability. Always distinguish CIDP (symmetric proximal+distal sensorimotor) from MMN (asymmetric pure motor with conduction block) and check anti-GM1 antibodies in any asymmetric pure motor demyelinating neuropathy before initiating treatment.

S5. IVIG, SCIG, Steroids, PLEX, and Rituximab

First-Line Treatment Options

Three first-line options have equivalent efficacy in classical CIDP per multiple randomized trials. Selection individualizes based on tolerability, access, comorbidities, and patient preference. CIDP treatment response: IVIG vs rituximab by phenotype, with escalation ladderGrouped bar chart of approximate response rates: in classical CIDP, first-line IVIG, PLEX or steroids achieve about 70 to 80 percent response while rituximab achieves about 40 to 50 percent in refractory cases. In autoimmune nodopathies, IVIG response is poor or absent while rituximab achieves about 70 to 80 percent. A stepped ladder shows escalation from first-line immunotherapy to rituximab and finally to other refractory agents.Treatment Response by Phenotype & Escalation Ladder100%50%0%70-80%IVIG/PLEX/steroid40-50%rituximab(refractory)Classical CIDPpoorIVIG70-80%rituximabNodopathiesKey: nodopathies fail IVIG — test antibodies before escalatingIVIG-refractory @ 12 wk → nodal/paranodal panel + POEMS (VEGF, IFE)Rituximab 1000 mg IV days 0 & 14, then every 6 months x 18-24 moApproximate ranges — not institutional outcome dataEscalation ladder1. First-line immunotherapyIVIG 2 g/kg → SCIG / PLEX / steroids2. Rituximabnodopathy 1st-line / refractory 2nd3. Refractory agentscyclophosphamide, efgartigimod, HSCT

AgentInductionMaintenanceComments
IVIG (preferred for most)2 g/kg total over 2-5 days1 g/kg every 3 weeks OR 0.4 g/kg weeklyRapid onset; well tolerated; expensive; requires infusion access
SCIG (Hizentra / IgPro20)After IVIG induction0.2-0.4 g/kg SC weeklyApproved for CIDP maintenance; equivalent efficacy; home self-administration; better tolerability than IVIG
Plasma exchange (PLEX)5-7 sessions every other day, 1.5 plasma volume eachRepeat at 2-6 week intervals as neededEquivalent efficacy; requires central venous access; less practical for chronic maintenance
CorticosteroidsPrednisone 60-80 mg PO daily or pulse IV methylprednisolone 500-1000 mg weeklyGradual taper over 6-12 months; alternate-day dosing preferred for chronicEffective but long-term toxicity (osteoporosis, diabetes, infection); best for patients who can taper

SCIG — Increasingly Preferred for Maintenance

Subcutaneous immunoglobulin (SCIG) has emerged as a preferred maintenance modality in modern CIDP practice. Hizentra (IgPro20) is approved for CIDP maintenance based on the PATH trial demonstrating equivalent efficacy to IVIG with improved tolerability and patient autonomy. Advantages:

  • Self-administration at home eliminates infusion center visits
  • Stable IgG levels avoid “wear-off” effects between IVIG infusions
  • Lower systemic adverse event burden (less headache, nausea, infusion reactions)
  • Patient quality of life improvement documented
  • Cost-effective for long-term maintenance compared to IVIG

Limitations include local injection site reactions (mild and generally well tolerated), need for 1-3 injection sites per dose, and slower onset for acute relapses (IVIG preferred for acute exacerbations even in SCIG-maintained patients).

Second-Line: Rituximab

Rituximab is indicated in two scenarios:

  • First-line for autoimmune nodopathies (anti-NF155, CNTN1, Caspr1, NF186) given dramatically better response than IVIG
  • Second-line for refractory classical CIDP after failure of IVIG, PLEX, and steroids

Dosing: 1000 mg IV at days 0 and 14, followed by maintenance every 6 months for 18-24 months. Response in nodopathies is typically 70-80 percent; in refractory classical CIDP approximately 40-50 percent. Monitor for B-cell depletion, hypogammaglobulinemia, and PCP prophylaxis with prednisone >20 mg.

Other Second-Line and Refractory Therapies

AgentDosingComments
CyclophosphamideIV 750 mg/m2 monthly or oral 1-2 mg/kg dailyRefractory severe disease; substantial toxicity
Mycophenolate mofetil1000 mg PO BIDSteroid-sparing; modest evidence
Azathioprine2-3 mg/kg PO daily (check TPMT first)Older steroid-sparing option
Cyclosporine / tacrolimusTrough-guided dosingSelected refractory cases
Hematopoietic stem cell transplantExperimentalSeverely refractory disease; specialty centers
Efgartigimod (FcRn antagonist)Approved 2024Approved for CIDP; reduces IgG levels; alternative for IVIG-refractory

Treatment Response Assessment

  • Initial response assessment at 4-12 weeks after treatment initiation; meaningful improvement in strength (MRC sum score), function (INCAT disability score, Rasch-built Overall Disability Scale), and patient-reported quality of life
  • Maintenance reassessment every 6-12 months once stable
  • Treatment withdrawal trial after 6-12 months of remission; approximately one-third of patients enter sustained remission allowing therapy discontinuation
  • Relapse monitoring with serial neurologic examination and patient self-monitoring; resume or escalate therapy at first signs of recurrence

Adjunctive Supportive Care

  • Physical and occupational therapy for strength, balance, mobility, and activities of daily living
  • Neuropathic pain management: gabapentin, pregabalin, duloxetine, amitriptyline
  • Mobility aids: ankle-foot orthoses for foot drop, walker, wheelchair as needed
  • Fatigue management: pacing, exercise programs, sleep optimization
  • Mental health support: depression and anxiety common in chronic neuromuscular disease
  • Vaccinations: pneumococcal, influenza, COVID-19; avoid live vaccines during immunosuppression

S6. Practice Insights — Lessons from the Neuromuscular Clinic

(The content below synthesizes published clinical patterns and expert consensus rather than first-person case reports.) After managing many CIDP patients across the neuromuscular clinic over the past decade — ranging from textbook typical CIDP that responds beautifully to IVIG within weeks to atypical nodopathies that confounded years of IVIG escalation before rituximab transformed their trajectory — clinicians have learned that the most consequential decisions are made in two places: the initial subtype classification (typical vs atypical vs nodopathy) and the recognition of IVIG-refractory disease as a trigger for nodopathy and POEMS workup. In experienced hands, the patients who do worst are the ones whose anti-NF155 antibody was never sent and who received years of inadequate IVIG before rituximab was finally tried.

1. Nodal/paranodal antibody panel on every CIDP at diagnosis, not just refractory

The single highest-yield diagnostic rule in experienced practice has shifted over the past 5 years: experienced clinicians now send the nodal/paranodal antibody panel (anti-NF155, anti-CNTN1, anti-Caspr1, anti-NF186) at INITIAL CIDP diagnosis, not only when IVIG fails. The reason is that identifying a nodopathy upfront means starting rituximab directly rather than the typical 12-week IVIG trial that does not work and delays effective therapy. The cost of the antibody panel is trivial against the cost of months of inadequate treatment.

2. IVIG-refractory CIDP = check nodopathy AND POEMS, not just escalate dose

When a CIDP patient fails to respond to first-line IVIG within 12 weeks, experienced practice is to investigate alternative diagnoses before escalating IVIG dose or switching to PLEX. The two most consequential alternative diagnoses are autoimmune nodopathy (rituximab responsive) and POEMS syndrome (lenalidomide-ASCT responsive). The standard workup at IVIG failure includes nodal/paranodal antibody panel, serum and urine immunofixation, serum free light chains, serum VEGF, and FDG-PET. Identifying either entity completely changes management.

3. SCIG transition for any patient on stable IVIG maintenance

In experienced hands, the quality of life difference between IVIG (every 3 weeks at infusion center) and SCIG (home self-administration weekly) is enormous, and SCIG efficacy is equivalent for maintenance. The standard now is to offer SCIG transition to any CIDP patient stable on IVIG maintenance for at least 6 months, particularly those who travel for work, have young families, or struggle with infusion center logistics. The PATH trial established equivalent efficacy and patient quality of life improvement is consistent in experienced practice.

4. Subtype recognition shapes prognosis and treatment selection

The five EFNS/PNS clinical subtypes have substantially different treatment response profiles and prognoses that have implications for counseling and treatment selection. In experienced practice, MADSAM responds well to IVIG and rituximab but slower than typical CIDP; DADS often associated with anti-MAG IgM responds poorly to IVIG but better to rituximab; pure motor must be distinguished from MMN (steroids worsen MMN); pure sensory subtypes have slower clinical response and require patience with treatment trials. Subtype recognition at the first visit shapes the entire management arc.

Illustrative Scenario —.(Composite teaching scenario assembled from published patterns; not an individual patient.) A man in his early 60s presented to the neuromuscular clinic with progressive weakness, sensory loss, and prominent action tremor over 6 months. Examination revealed symmetric distal-greater-than-proximal weakness, severe sensory ataxia on Romberg testing, areflexia, and a fine-amplitude action tremor of both hands. Nerve conduction studies showed severe demyelinating physiology with prolonged distal motor latencies (median 11.5 ms), reduced motor conduction velocities (peroneal 22 m/s), and conduction block in multiple nerves. CSF showed markedly elevated protein at 285 mg/dL with normal cell count. Initial diagnosis of typical CIDP led to IVIG 2 g/kg loading followed by 1 g/kg every 3 weeks for 4 cycles with minimal improvement. The neuromuscular team recognized atypical features (tremor, severe sensory ataxia, very high CSF protein, IVIG refractoriness) and sent the nodal/paranodal antibody panel that returned anti-NF155 IgG4 positive. Diagnosis was revised to anti-NF155 autoimmune nodopathy. He was started on rituximab 1000 mg IV at days 0 and 14, with maintenance every 6 months. Within 4 months of rituximab initiation his strength had improved substantially, the tremor resolved, and sensory ataxia improved. CSF protein declined to 95 mg/dL at 6 months. At 18-month follow-up he had returned to independent ambulation and resumed his work as an engineer.
Four lessons compressed into one case: the atypical features (tremor, severe sensory ataxia, very high CSF protein, IVIG refractoriness) should have prompted nodal/paranodal antibody testing at initial presentation rather than after 4 IVIG cycles; the anti-NF155 IgG4 nodopathy explained the IVIG refractoriness through targeting the IgG4-dependent antibody class; rituximab produced the dramatic response that IVIG could not; and earlier antibody testing would have shortened the 4-month delay before effective treatment was initiated.

Personal protocol adjustments beyond the published guideline

  • Nodal/paranodal antibody panel at INITIAL CIDP diagnosis, not only refractory. The guideline supports this for refractory cases; experienced practice has shifted to upfront testing because identifying a nodopathy at diagnosis means starting rituximab directly rather than 12 weeks of ineffective IVIG.
  • IVIG-refractory = simultaneous nodopathy + POEMS workup. The guideline says consider alternative diagnoses; experienced practice is a simultaneous battery (nodal antibodies + immunofixation + free light chains + VEGF + FDG-PET) sent the same week the IVIG failure is recognized.
  • SCIG transition offer to every IVIG-stable patient at 6 months. The guideline supports SCIG as alternative; experienced practice actively offers transition to optimize patient quality of life because efficacy is equivalent and lifestyle benefit is substantial.
  • Subtype-specific counseling at diagnosis. Experienced practice spends the first visit ensuring the patient understands which CIDP subtype they have, the expected treatment response timeline, and the prognosis differences, because subtypes have substantially different trajectories that shape patient expectations.
CIDP framework Four-panel visualization: five clinical subtype distribution pie, EFNS/PNS 2021 electrodiagnostic criteria thresholds table, nodopathy antibody-clinical-treatment matrix, and treatment selection algorithm with IVIG-refractory branch. Personal CIDP Framework — Four Pillars 1. EFNS/PNS 2021 Five Clinical Subtypes Typical ~50% MADSAM/Lewis-Sumner ~15% DADS ~10% Pure motor ~10% Pure sensory ~10% Subtype shapes treatment + prognosis 2. NCS Demyelination Thresholds Feature Threshold Distal motor latency > 150% ULN Motor conduction velocity < 70% LLN F-wave latency > 120% ULN F-wave absent in 2 nerves Conduction block > 50% drop Temporal dispersion > 30% increase Need ≥2 nerves with criteria for definite CIDP 3. Autoimmune Nodopathy Antibodies Antibody Phenotype Treatment Anti-NF155 tremor, ataxia, ↑↑CSF Rituximab Anti-CNTN1 severe motor, nephrotic Rituximab Anti-Caspr1 sensory + pain Rituximab Anti-NF186 variable Rituximab Anti-MAG IgM DADS + IgM gammopathy RTX±IVIG Anti-GM1 (MMN) asym pure motor IVIG only Key: Nodopathies = IgG4 = IVIG fails Send panel at DIAGNOSIS, not only at IVIG failure 4. Treatment Selection Algorithm CIDP diagnosed + nodopathy panel sent Nodopathy + Rituximab first-line 1000 mg x 2 then q6mo Classical CIDP IVIG 2g/kg load → 1g/kg q3wk OR SCIG IVIG refractory @ 12wk? Check POEMS (VEGF/IFE) + redo nodopathy + RTX

Four-panel personal framework: the five EFNS/PNS 2021 clinical subtypes with relative frequencies (panel 1), the electrodiagnostic demyelination thresholds requiring at least 2 nerves to meet criteria (panel 2), the nodal/paranodal antibody matrix mapping each antibody to its distinctive phenotype and preferred treatment (panel 3), and the treatment selection algorithm with the critical IVIG-refractory branch triggering POEMS and repeat nodopathy workup (panel 4). Approximate ranges; not institutional outcome data.

S7. Frequently Asked Questions

Q1. How is CIDP defined by the EFNS/PNS 2021 criteria?
The EFNS/PNS 2021 criteria define CIDP by combination of clinical and electrodiagnostic features. Typical CIDP requires symmetric proximal AND distal weakness, sensory loss, and absent or diminished reflexes with progression or relapse over at least 8 weeks. Electrodiagnostic confirmation requires demyelinating motor nerve conduction features (prolonged distal motor latency, slowed conduction velocity, prolonged F-wave latency, conduction block, or temporal dispersion) meeting specified thresholds in at least 2 nerves. The criteria recognize five clinical subtypes: typical CIDP, distal acquired demyelinating symmetric (DADS), multifocal (MADSAM/Lewis-Sumner), pure motor, and pure sensory. CSF protein elevation with normal cell count (albuminocytologic dissociation) and MRI demonstration of nerve root or plexus enlargement and gadolinium enhancement are supportive but not required.
Q2. What are the autoimmune nodopathies and how do they differ from CIDP?
Autoimmune nodopathies are now formally separated from CIDP in the EFNS/PNS 2021 criteria as a distinct disease entity defined by antibodies against nodal or paranodal proteins. The four major antibodies are anti-neurofascin 155 (NF155), anti-contactin-1 (CNTN1), anti-contactin-associated protein 1 (Caspr1), and anti-neurofascin 186 (NF186). Clinical features differing from typical CIDP include rapid onset and severe weakness, tremor (especially anti-NF155), sensory ataxia, cranial nerve involvement, very high CSF protein, IgG4 subclass predominance of antibodies, poor or absent response to IVIG, and dramatic response to rituximab. Recognition is essential because the treatment paradigm differs — rituximab first-line for nodopathies whereas IVIG remains first-line for classical CIDP. Send the nodal/paranodal antibody panel in any IVIG-refractory CIDP.
Q3. What is the first-line treatment for typical CIDP?
First-line treatment for typical CIDP is IVIG, plasma exchange, or corticosteroids, with comparable efficacy across all three but differing tolerability and practical considerations. IVIG is dosed at 2 g/kg total over 2 to 5 days for induction, then 1 g/kg every 3 weeks (or 0.4 g/kg weekly) for maintenance; rapid onset, low toxicity, but expensive and requires repeat infusions. Subcutaneous immunoglobulin (SCIG, IgPro20/Hizentra) at 0.2-0.4 g/kg weekly is now approved for CIDP maintenance with equivalent efficacy and improved tolerability and patient autonomy compared to IVIG. Plasma exchange (5-7 sessions every other day) has equivalent efficacy but requires vascular access. Corticosteroids (prednisone 60-80 mg daily with taper) are effective but carry long-term toxicity burden. Choice individualizes based on response, tolerability, access, and patient preference.
Q4. What are the five EFNS/PNS clinical subtypes of CIDP?
EFNS/PNS 2021 recognizes five clinical CIDP subtypes. Typical CIDP (~50%) shows symmetric proximal and distal weakness with sensory involvement. Distal acquired demyelinating symmetric (DADS, ~10%) shows distal-predominant symmetric weakness and sensory loss, frequently associated with anti-MAG IgM (more accurately classified as a paraproteinemic neuropathy than CIDP). MADSAM (multifocal acquired demyelinating sensory and motor, Lewis-Sumner syndrome, ~15%) shows asymmetric multifocal sensorimotor deficits resembling mononeuritis multiplex but with demyelinating physiology. Pure motor CIDP (~10%) shows symmetric weakness without sensory involvement (must distinguish from multifocal motor neuropathy, MMN). Pure sensory CIDP (~10%) shows sensory ataxia and sensory loss without weakness. Each subtype has distinct treatment response profile and prognosis.
Q5. How is CIDP distinguished from Guillain-Barre syndrome and POEMS?
CIDP versus GBS: timing distinguishes them. GBS reaches nadir within 4 weeks of onset; CIDP progresses or relapses over more than 8 weeks. GBS treatment is acute (IVIG or PLEX for 5 days), CIDP requires ongoing maintenance immunotherapy. Some patients have acute-onset CIDP (A-CIDP) that initially appears as GBS but then continues to progress beyond 8 weeks. CIDP versus POEMS: both feature demyelinating polyneuropathy and IVIG resistance, but POEMS has additional features: organomegaly (hepatosplenomegaly), endocrinopathy (multiple), monoclonal protein (almost always lambda), skin changes (hyperpigmentation, hemangiomas), and dramatically elevated serum VEGF. Always check serum and urine immunofixation, serum free light chain, serum VEGF, and skeletal survey in any refractory CIDP to rule out POEMS.
Q6. When is rituximab indicated in CIDP?
Rituximab is indicated for CIDP patients with confirmed autoimmune nodopathy (anti-NF155, anti-CNTN1, anti-Caspr1, anti-NF186 antibodies positive on nodal/paranodal antibody panel), and for refractory classical CIDP that has failed first-line IVIG, plasma exchange, and corticosteroids. The dramatic response of nodopathies to rituximab (often 70-80 percent response rate) contrasts with the typical refractoriness of these patients to IVIG, making early antibody testing essential. Standard dosing is rituximab 1000 mg IV at days 0 and 14, with maintenance every 6 months for 18-24 months. For refractory CIDP without nodopathy, rituximab response rates are lower (~40-50 percent) but represent a reasonable second-line escalation when first-line therapies have failed.
Q7. What is the role of nerve conduction studies in CIDP diagnosis?
Nerve conduction studies are essential for CIDP diagnosis because they distinguish demyelinating from axonal neuropathy. EFNS/PNS 2021 demyelinating criteria require, in at least 2 motor nerves: prolonged distal motor latency >50% of upper limit of normal (ULN), reduced motor conduction velocity <70% of lower limit of normal, prolonged F-wave latency >20% above ULN (>50% if amplitude greatly reduced), absent F-waves, conduction block (>50% reduction in CMAP amplitude between proximal and distal stimulation), or temporal dispersion (>30% increase in CMAP duration between proximal and distal stimulation). Sensory studies often show reduced amplitudes or absent sural responses. Atypical patterns (very distal demyelination only in DADS, multifocal block in MADSAM) require modified electrodiagnostic interpretation. Skilled electromyographer is essential for correct interpretation.
Q8. What is the long-term prognosis and treatment response in CIDP?
Approximately 70-80 percent of CIDP patients respond to first-line therapy (IVIG, PLEX, or steroids) with substantial functional improvement. The remaining 20-30 percent are refractory and require second-line escalation with rituximab, cyclophosphamide, or other agents. Long-term outcomes show roughly one third of patients enter sustained remission allowing therapy withdrawal, one third require ongoing maintenance immunotherapy, and one third have refractory or progressive disease with disability accumulation. Disease-related disability includes weakness, fatigue, neuropathic pain, balance impairment, and reduced quality of life. Lifelong neurology follow-up with periodic clinical assessment, nerve conduction studies, and treatment adjustment is required. Prognosis is generally better in typical CIDP than in pure sensory or DADS subtypes, and worse in autoimmune nodopathies before recognition (now improved with rituximab).
↑

Leave a Reply

Your email address will not be published. Required fields are marked *